The closure, broken by Endpoints News on Thursday after speaking with two former employees, appears to have officially ...
In a recent interview, Robert Fried, CEO of Niagen Bioscience, delves into the science of aging and the pivotal role of a molecule known as NAD (nicotinamide adenine dinucleotide). He explains how NAD ...
Niagen Bioscience continues to see improving demand for Tru Niagen, strengthening cash generation, and a debt-free balance ...
Serán Bioscience, LLC, in collaboration with leading developer and design-builder Mortenson, hosted a topping-out ceremony ...
Harvard Bioscience has yet another leadership shakeup as the Holliston-based biotech firm’s CEO is set to retire and two new members have been added to its board of directors in an attempt to regain ...
Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating ...
Skye Bioscience Inc. (NASDAQ:SKYE) shares gained 5.3% in premarket trading on Monday after the company revealed a ...
On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody. In the first ...
In the longevity and wellness space, Niagen Bioscience is charting a course defined by both scientific rigor and an unwavering commitment to responsible innovation Niagen Bioscience (NASDAQ: NAGE, ...
Harvard Bioscience, Inc. has announced that John Duke, a current Board member, will succeed Jim Green as President and CEO effective July 28, 2025, as Green prepares to retire after over eight years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback